Parkinson's disease,cortical dysfunction,and alpha‐synuclein |
| |
| Authors: | John N. Caviness MD Lih‐Fen Lue PhD Thomas G. Beach MD PhD Joseph G. Hentz MS Charles H. Adler MD PhD Lucia Sue Ramin Sadeghi Erika Driver‐Dunckley MD Virgilio G. Evidente MD Marwan N. Sabbagh MD Holly A. Shill MD Douglas G. Walker PhD |
| |
| Affiliation: | 1. Department of Neurology, Mayo Clinic, Scottsdale, Arizona, USA;2. Laboratory of Neuroinflammation, Banner Sun Health Research Institute, Sun City, Arizona, USA;3. Civin Laboratory of Neuropathology, Banner Sun Health Research Institute, Sun City, Arizona, USA;4. Department of Biostatistics, Mayo Clinic, Scottsdale, Arizona, USA;5. Cleo Roberts Clinical Research Center, Banner Sun Health Research Institute, Sun City, Arizona, USA |
| |
| Abstract: | The ability to understand how Parkinson's disease neurodegeneration leads to cortical dysfunction will be critical for developing therapeutic advances in Parkinson's disease dementia. The overall purpose of this project was to study the small‐amplitude cortical myoclonus in Parkinson's disease as an in vivo model of focal cortical dysfunction secondary to Parkinson's disease neurodegeneration. The objectives were to test the hypothesis that cortical myoclonus in Parkinson's disease is linked to abnormal levels of α‐synuclein in the primary motor cortex and to define its relationship to various biochemical, clinical, and pathological measures. The primary motor cortex was evaluated for 11 Parkinson's disease subjects with and 8 without electrophysiologically confirmed cortical myoclonus (the Parkinson's disease + myoclonus group and the Parkinson's disease group, respectively) who had premortem movement and cognitive testing. Similarly assessed 9 controls were used for comparison. Measurements for α‐synuclein, Aβ‐42 peptide, and other biochemical measures were made in the primary motor cortex. A 36% increase in α‐synuclein was found in the motor cortex of Parkinson's disease + myoclonus cases when compared with Parkinson's disease without myoclonus. This occurred without significant differences in insoluble α‐synuclein, phosphorylated to total α‐synuclein ratio, or Aβ‐42 peptide levels. Higher total motor cortex α‐synuclein levels significantly correlated with the presence of cortical myoclonus but did not correlate with multiple clinical or pathological findings. These results suggest an association between elevated α‐synuclein and the dysfunctional physiology arising from the motor cortex in Parkinson's disease + myoclonus cases. Alzheimer's disease pathology was not associated with cortical myoclonus in Parkinson's disease. Cortical myoclonus arising from the motor cortex is a model to study cortical dysfunction in Parkinson's disease. © 2011 Movement Disorder Society |
| |
| Keywords: | Parkinson's disease myoclonus cortex alpha‐synuclein dementia |
|
|
